Dose/effect relationships for brain metastases
Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the quest...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1998 |
|---|
| Umfang: |
5 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Journal of cancer research and clinical oncology - 1904, 124(1998) vom: Juni, Seite 346-350 |
| Übergeordnetes Werk: |
volume:124 ; year:1998 ; month:06 ; pages:346-350 ; extent:5 |
| Links: |
|---|
| Katalog-ID: |
NLEJ205280714 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ205280714 | ||
| 003 | DE-627 | ||
| 005 | 20210706173039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1998 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ205280714 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Dose/effect relationships for brain metastases |
| 264 | 1 | |c 1998 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Nieder, Carsten |4 oth | |
| 700 | 1 | |a Nestle, Ursula |4 oth | |
| 700 | 1 | |a Walter, Karin |4 oth | |
| 700 | 1 | |a Niewald, Marcus |4 oth | |
| 700 | 1 | |a Schnabel, Klaus |4 oth | |
| 773 | 0 | 8 | |i in |t Journal of cancer research and clinical oncology |d 1904 |g 124(1998) vom: Juni, Seite 346-350 |w (DE-627)NLEJ188987657 |w (DE-600)1459285-x |x 1432-1335 |7 nnns |
| 773 | 1 | 8 | |g volume:124 |g year:1998 |g month:06 |g pages:346-350 |g extent:5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s004320050181 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 124 |j 1998 |c 6 |h 346-350 |g 5 | ||
| matchkey_str |
article:14321335:1998----::oefeteainhpfrri |
|---|---|
| hierarchy_sort_str |
1998 |
| publishDate |
1998 |
| allfields |
(DE-627)NLEJ205280714 DE-627 ger DE-627 rakwb eng Dose/effect relationships for brain metastases 1998 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. Springer Online Journal Archives 1860-2002 Nieder, Carsten oth Nestle, Ursula oth Walter, Karin oth Niewald, Marcus oth Schnabel, Klaus oth in Journal of cancer research and clinical oncology 1904 124(1998) vom: Juni, Seite 346-350 (DE-627)NLEJ188987657 (DE-600)1459285-x 1432-1335 nnns volume:124 year:1998 month:06 pages:346-350 extent:5 http://dx.doi.org/10.1007/s004320050181 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 124 1998 6 346-350 5 |
| spelling |
(DE-627)NLEJ205280714 DE-627 ger DE-627 rakwb eng Dose/effect relationships for brain metastases 1998 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. Springer Online Journal Archives 1860-2002 Nieder, Carsten oth Nestle, Ursula oth Walter, Karin oth Niewald, Marcus oth Schnabel, Klaus oth in Journal of cancer research and clinical oncology 1904 124(1998) vom: Juni, Seite 346-350 (DE-627)NLEJ188987657 (DE-600)1459285-x 1432-1335 nnns volume:124 year:1998 month:06 pages:346-350 extent:5 http://dx.doi.org/10.1007/s004320050181 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 124 1998 6 346-350 5 |
| allfields_unstemmed |
(DE-627)NLEJ205280714 DE-627 ger DE-627 rakwb eng Dose/effect relationships for brain metastases 1998 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. Springer Online Journal Archives 1860-2002 Nieder, Carsten oth Nestle, Ursula oth Walter, Karin oth Niewald, Marcus oth Schnabel, Klaus oth in Journal of cancer research and clinical oncology 1904 124(1998) vom: Juni, Seite 346-350 (DE-627)NLEJ188987657 (DE-600)1459285-x 1432-1335 nnns volume:124 year:1998 month:06 pages:346-350 extent:5 http://dx.doi.org/10.1007/s004320050181 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 124 1998 6 346-350 5 |
| allfieldsGer |
(DE-627)NLEJ205280714 DE-627 ger DE-627 rakwb eng Dose/effect relationships for brain metastases 1998 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. Springer Online Journal Archives 1860-2002 Nieder, Carsten oth Nestle, Ursula oth Walter, Karin oth Niewald, Marcus oth Schnabel, Klaus oth in Journal of cancer research and clinical oncology 1904 124(1998) vom: Juni, Seite 346-350 (DE-627)NLEJ188987657 (DE-600)1459285-x 1432-1335 nnns volume:124 year:1998 month:06 pages:346-350 extent:5 http://dx.doi.org/10.1007/s004320050181 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 124 1998 6 346-350 5 |
| allfieldsSound |
(DE-627)NLEJ205280714 DE-627 ger DE-627 rakwb eng Dose/effect relationships for brain metastases 1998 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. Springer Online Journal Archives 1860-2002 Nieder, Carsten oth Nestle, Ursula oth Walter, Karin oth Niewald, Marcus oth Schnabel, Klaus oth in Journal of cancer research and clinical oncology 1904 124(1998) vom: Juni, Seite 346-350 (DE-627)NLEJ188987657 (DE-600)1459285-x 1432-1335 nnns volume:124 year:1998 month:06 pages:346-350 extent:5 http://dx.doi.org/10.1007/s004320050181 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 124 1998 6 346-350 5 |
| language |
English |
| source |
in Journal of cancer research and clinical oncology 124(1998) vom: Juni, Seite 346-350 volume:124 year:1998 month:06 pages:346-350 extent:5 |
| sourceStr |
in Journal of cancer research and clinical oncology 124(1998) vom: Juni, Seite 346-350 volume:124 year:1998 month:06 pages:346-350 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Journal of cancer research and clinical oncology |
| authorswithroles_txt_mv |
Nieder, Carsten @@oth@@ Nestle, Ursula @@oth@@ Walter, Karin @@oth@@ Niewald, Marcus @@oth@@ Schnabel, Klaus @@oth@@ |
| publishDateDaySort_date |
1998-06-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188987657 |
| id |
NLEJ205280714 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ205280714</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706173039.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1998 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ205280714</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dose/effect relationships for brain metastases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nieder, Carsten</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nestle, Ursula</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walter, Karin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niewald, Marcus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schnabel, Klaus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of cancer research and clinical oncology</subfield><subfield code="d">1904</subfield><subfield code="g">124(1998) vom: Juni, Seite 346-350</subfield><subfield code="w">(DE-627)NLEJ188987657</subfield><subfield code="w">(DE-600)1459285-x</subfield><subfield code="x">1432-1335</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:124</subfield><subfield code="g">year:1998</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:346-350</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s004320050181</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">124</subfield><subfield code="j">1998</subfield><subfield code="c">6</subfield><subfield code="h">346-350</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188987657 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-1335 |
| topic_title |
Dose/effect relationships for brain metastases |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c n cn u n un k w kw m n mn k s ks |
| hierarchy_parent_title |
Journal of cancer research and clinical oncology |
| hierarchy_parent_id |
NLEJ188987657 |
| hierarchy_top_title |
Journal of cancer research and clinical oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188987657 (DE-600)1459285-x |
| title |
Dose/effect relationships for brain metastases |
| spellingShingle |
Dose/effect relationships for brain metastases |
| ctrlnum |
(DE-627)NLEJ205280714 |
| title_full |
Dose/effect relationships for brain metastases |
| journal |
Journal of cancer research and clinical oncology |
| journalStr |
Journal of cancer research and clinical oncology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1998 |
| contenttype_str_mv |
zzz |
| container_start_page |
346 |
| container_volume |
124 |
| physical |
5 |
| format_se |
Elektronische Aufsätze |
| title_sort |
dose/effect relationships for brain metastases |
| title_auth |
Dose/effect relationships for brain metastases |
| abstract |
Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. |
| abstractGer |
Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. |
| abstract_unstemmed |
Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Dose/effect relationships for brain metastases |
| url |
http://dx.doi.org/10.1007/s004320050181 |
| remote_bool |
true |
| author2 |
Nieder, Carsten Nestle, Ursula Walter, Karin Niewald, Marcus Schnabel, Klaus |
| author2Str |
Nieder, Carsten Nestle, Ursula Walter, Karin Niewald, Marcus Schnabel, Klaus |
| ppnlink |
NLEJ188987657 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| up_date |
2024-07-06T03:18:38.573Z |
| _version_ |
1803798098554650624 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ205280714</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706173039.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1998 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ205280714</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dose/effect relationships for brain metastases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Purpose: Only in selected patients with brain metastases, e.g. those with controlled or absent extracranial tumour, may application of higher total doses of radiotherapy improve survival. However, local control is the prerequisite for long-term survival. This study aimed to answer the question whether or not local control can be improved by dose escalation. Methods: Computed tomography scans of 322 patients were analysed in order to evaluate the best local result after radiotherapy and the time to local progression. Total doses of 25–60 Gy were administered (single doses 1.8–5 Gy). The biologically effective dose (BED10) was calculated for statistical evaluation according to the linear-quadratic model assuming an α/β-value of Gy. It ranged between 37.5 Gy and 72 Gy. Results: The best local result was dependent on the number of brain metastases, BED and the histology of the primary tumour (small-cell and breast carcinoma had higher remission rates than squamous-cell carcinoma, non-breast adenocarcinoma and others). Partial remission rates significantly increased with BED, whereas complete remission rates did not improve. Histology was the only significant factor in multivariate tests. The 1-year-failure rate improved with increased BED from 44% to 31% (P > 0.05). Overall survival (median 3 months) was not dependent on total dose. Conclusions: Previous studies suggested that a prolongation of survival can be achieved through better local management (e.g. surgery plus radiotherapy, radiosurgery). However, it is still uncertain whether conventional external-beam radiotherapy with higher total doses leads to comparable results. The optimum dose level still has to be established. For squamous-cell carcinoma and adenocarcinoma a BED of at least 72 Gy seems to be necessary, for small-cell and breast carcinoma, doses between 48 Gy and 60 Gy might be sufficient. The important influence of tumour histology on local remission and progression-free survival should be considered when planning future clinical trials.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nieder, Carsten</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nestle, Ursula</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walter, Karin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niewald, Marcus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schnabel, Klaus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of cancer research and clinical oncology</subfield><subfield code="d">1904</subfield><subfield code="g">124(1998) vom: Juni, Seite 346-350</subfield><subfield code="w">(DE-627)NLEJ188987657</subfield><subfield code="w">(DE-600)1459285-x</subfield><subfield code="x">1432-1335</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:124</subfield><subfield code="g">year:1998</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:346-350</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s004320050181</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">124</subfield><subfield code="j">1998</subfield><subfield code="c">6</subfield><subfield code="h">346-350</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.3998413 |